AstraZeneca reported an increase in second-quarter revenue, driven by income from licensing deals, though profit continued to fall as the company plowed heavy investment into new drugs it hopes will replace its old blockbusters.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 07/29/2015 - 11:54pm
AstraZeneca reported an increase in second-quarter revenue, driven by income from licensing deals, though profit continued to fall as the company plowed heavy investment into new drugs it hopes will replace its old blockbusters.